Inhibrx EBITDA
Was ist das EBITDA von Inhibrx?
EBITDA von Inhibrx, Inc. ist -$111.79
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Inhibrx
Was macht Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Unternehmen mit ebitda ähnlich Inhibrx
- Geron hat EBITDA von -$113.06
- Pliant Therapeutics hat EBITDA von -$112.61
- Avalara Inc hat EBITDA von -$112.60
- Christine International hat EBITDA von -¥112.46
- Albireo Pharma Inc hat EBITDA von -$112.20
- Kadmon hat EBITDA von -$112.01
- Inhibrx hat EBITDA von -$111.79
- Apollo Future Mobility hat EBITDA von -HKD$111.73
- Ballard Power Systems hat EBITDA von -$111.66
- Housing Development and Infrastructure hat EBITDA von -₨111.53
- ALX Oncology hat EBITDA von -$111.40
- Provention Bio hat EBITDA von -$111.35
- Litian Pictures hat EBITDA von -¥110.92